東陽光(600673.SH)：擬收購生化製藥100%股權 明起復牌
格隆匯 7 月 28日丨東陽光(600673.SH)公佈，此次重組交易的交易對象為藥業股份，交易標的為生化製藥的100%股權。在此次重組交易之前，藥業股份擬開展內部重組，主要目的為將其大環內酯類原料藥與中間體、鹽酸林可黴素原料藥與中間體、酶製劑等業務相關的資產負債、資質、人員和業務下沉至其全資子公司生化製藥。在完成上述內部重組後，公司擬以發行股份的方式向藥業股份購買其持有的生化製藥的100%股權。此次交易完成後，公司將持有生化製藥100%股權。
根據相關規定，經向上海證券交易所申請，公司股票將於2020年7月29日開市起復牌。
截至預案摘要簽署日，上述交易對方內部重組及標的資產的審計和評估工作尚未完成，因此本次交易的具體價格尚未確定。此次交易所涉及的財務數據和評估結果將由具備《證券法》等法律法規及中國證監會規定的從事證券服務資質的會計師事務所、評估機構出具報告，並在重組報告書中予以披露。標的資產的最終交易價格將以評估機構出具的評估報告作為參考依據，由交易雙方協商確定，最終向交易對方支付的股份數量將在重組報告書予以披露。
公司擬向不超過35名特定投資者非公開發行股份募集配套資金，募集配套資金的總金額不超過此次發行股份購買標的資產交易對價的100%，且發行股份數量不超過上市公司此次交易前上市公司總股本的30%。募集配套資金擬用於支付相關交易税費以及中介機構費用、標的資產的項目建設、補充上市公司和標的資產流動資金、償還債務等，其中用於補充流動資金、償還債務的比例不應超過交易作價的25%。
公司的主營業務包括電子新材料、合金材料、化工產品、醫藥製造四大板塊。通過此次交易，生化製藥將成為公司的全資子公司，公司將獲得優質的大環內酯類原料藥與中間體、鹽酸林可黴素原料藥與中間體、酶製劑等板塊業務。此次交易是公司醫藥製造板塊業務的延伸，有利於公司促進產業整合、豐富公司產品結構，有利於提升上市公司的核心競爭力和盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
